Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
August 08, 2024 at 07:02 AM EDT
The success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|